

Jessica Cusato

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8127917/jessica-cusato-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

128
papers

1,795
citations

24
h-index

35
g-index

137
ext. papers

2,200
ext. citations

4.6
avg, IF

4.93
L-index

#	Paper	IF	Citations
128	Wastewater-based SARS-CoV-2 environmental monitoring for Piedmont, Italy. <i>Environmental Research</i> , 2022 , 203, 111901	7.9	3
127	A combined role for low vitamin D and low albumin circulating levels as strong predictors of worse outcome in COVID-19 patients.. <i>Irish Journal of Medical Science</i> , 2022 , 1	1.9	0
126	Antifungal Drug Plasma Exposures: A Possible Contribution of Vitamin D-Related Gene Variants. <i>Pharmaceuticals</i> , 2022 , 15, 630	5.2	
125	A description of Cannabinoid levels in Cannabis oil by high-performance liquid chromatography-mass spectrometry in a reference laboratory of North-Italy. <i>Phytomedicine</i> , 2022 , 102, 154218	6.5	0
124	A Non-Invasive Method for Detection of Antihypertensive Drugs in Biological Fluids: The Salivary Therapeutic Drug Monitoring.. <i>Frontiers in Pharmacology</i> , 2021 , 12, 755184	5.6	0
123	Obstetric and neonatal outcomes after SARS-CoV-2 infection in the first trimester of pregnancy: A prospective comparative study. <i>Journal of Obstetrics and Gynaecology Research</i> , 2021 ,	1.9	4
122	Validation and Clinical Application of a New Liquid Chromatography Coupled to Mass Spectrometry (HPLC-MS) Method for Dalbavancin Quantification in Human Plasma. <i>Separations</i> , 2021 , 8, 189	3.1	1
121	Longitudinal analysis of antibody response following SARS-CoV-2 infection in pregnancy: From the first trimester to delivery. <i>Journal of Reproductive Immunology</i> , 2021 , 144, 103285	4.2	9
120	Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. <i>British Journal of Clinical Pharmacology</i> , 2021 ,	3.8	2
119	Blood-Brain Barrier Impairment in Patients Living with HIV: Predictors and Associated Biomarkers. <i>Diagnostics</i> , 2021 , 11,	3.8	3
118	Analysis of Cannabinoids Concentration in Cannabis Oil Galenic Preparations: Harmonization between Three Laboratories in Northern Italy. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	1
117	Trend of 25-hydroxycholesterol and 27-hydroxycholesterol plasma levels in patients affected by active chronic hepatitis B virus infection and inactive carriers. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2021 , 210, 105854	5.1	3
116	The "scar" of a pandemic: Cumulative incidence of COVID-19 during the first trimester of pregnancy. <i>Journal of Medical Virology</i> , 2021 , 93, 537-540	19.7	31
115	Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma: Towards Individualized Dosing. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 89-102	6.2	2
114	Coronavirus disease 2019 and first-trimester spontaneous abortion: a case-control study of 225 pregnant patients. <i>American Journal of Obstetrics and Gynecology</i> , 2021 , 224, 391.e1-391.e7	6.4	45
113	Prenatal Biochemical and Ultrasound Markers in COVID-19 Pregnant Patients: A Prospective Case-Control Study. <i>Diagnostics</i> , 2021 , 11,	3.8	3
112	Serological and virological response in patients with hepatitis B virus genotype E treated with entecavir or tenofovir: a prospective study. <i>Archives of Virology</i> , 2021 , 166, 1125-1131	2.6	

111	Preterm birth is not associated with asymptomatic/mild SARS-CoV-2 infection per se: Pre-pregnancy state is what matters. <i>PLoS ONE</i> , 2021 , 16, e0254875	3.7	1
110	Long-Term Pharmacokinetics of Dalbavancin in ABSSSI and Osteoarticular Settings: A Real-Life Outpatient Context. <i>Biomedicines</i> , 2021 , 9,	4.8	1
109	Seasonal Variation of Antiretroviral Drug Exposure during the Year: The Experience of 10 Years of Therapeutic Drug Monitoring. <i>Biomedicines</i> , 2021 , 9,	4.8	1
108	Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 1772-1777	5.1	41
107	25-Hydroxyvitamin D Concentrations Are Lower in Patients with Positive PCR for SARS-CoV-2. <i>Nutrients</i> , 2020 , 12,	6.7	236
106	Calcaneal Quantitative Ultrasonography and Urinary Retinol-Binding Protein in Antiretroviral-Treated Patients With Human Immunodeficiency Virus in Uganda: A Pilot Study. <i>Journal of Infectious Diseases</i> , 2020 , 222, 263-272	7	1
105	Effect of Gender and Age on Voriconazole Trough Concentrations in Italian Adult Patients. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2020 , 45, 405-412	2.7	1
104	Validation of a UHPLC-MS/MS Method to Quantify Twelve Antiretroviral Drugs within Peripheral Blood Mononuclear Cells from People Living with HIV. <i>Pharmaceuticals</i> , 2020 , 14,	5.2	2
103	Cerebral white matter Hyperintensities in HIV-positive patients. <i>Brain Imaging and Behavior</i> , 2020 , 14, 10-18	4.1	5
102	Pharmacogenetic determinants of kidney-associated urinary and serum abnormalities in antiretroviral-treated HIV-positive patients. <i>Pharmacogenomics Journal</i> , 2020 , 20, 202-212	3.5	3
101	Influence of Vitamin D in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab. <i>Cancers</i> , 2019 , 11,	6.6	4
100	The Influence of Pharmacogenetic Variants in HIV/Tuberculosis Coinfected Patients in Uganda in the SOUTH Study. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 106, 450-457	6.1	7
99	Different Underlying Mechanism Might Explain the Absence of a Significant Difference in Area Under the Concentration-Time Curve of Linezolid for Different ABCB1 Genotypes. <i>Therapeutic Drug Monitoring</i> , 2019 , 41, 254-255	3.2	
98	Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate are not transported by Concentrative Nucleoside Transporter 2. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019 , 94, 202-204	2.9	1
97	SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 1035-1043	5.1	15
96	LC-MS application for therapeutic drug monitoring in alternative matrices. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019 , 166, 40-51	3.5	47
95	The effect of vitamin D pathway genes and deferasirox pharmacogenetics on liver iron in thalassaemia major patients. <i>Pharmacogenomics Journal</i> , 2019 , 19, 417-427	3.5	4
94	High efavirenz serum concentrations in TB/HIV-coinfected Ugandan adults with a CYP2B6 516 TT genotype on anti-TB treatment. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 135-138	5.1	5

93	Cannabinoids concentration variability in cannabis olive oil galenic preparations. <i>Journal of Pharmacy and Pharmacology</i> , 2018 , 70, 143-149	4.8	40
92	Pharmacogenetics of the anti-HCV drug sofosbuvir: a preliminary study. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 1659-1664	5.1	6
91	Vitamin D pathway genetic variants are able to influence sofosbuvir and its main metabolite pharmacokinetics in HCV mono-infected patients. <i>Infection, Genetics and Evolution</i> , 2018 , 60, 42-47	4.5	2
90	Vitamin D pathway gene polymorphisms and hepatocellular carcinoma in chronic hepatitis C-affected patients treated with new drugs. <i>Cancer Chemotherapy and Pharmacology</i> , 2018 , 81, 615-620	3.5	7
89	Symptomatic cerebrospinal fluid HIV-1 escape with no resistance-associated mutations following low-level plasma viremia. <i>Journal of NeuroVirology</i> , 2018 , 24, 132-136	3.9	4
88	Role of ribavirin in the treatment of hepatitis C virus-associated mixed cryoglobulinemia with interferon-free regimens. <i>Archives of Virology</i> , 2018 , 163, 961-967	2.6	5
87	Pharmacogenetic of voriconazole antifungal agent in pediatric patients. <i>Pharmacogenomics</i> , 2018 , 19, 913-925	2.6	10
86	Effect of ABCC2 and ABCG2 Gene Polymorphisms and CSF-to-Serum Albumin Ratio on Ceftriaxone Plasma and Cerebrospinal Fluid Concentrations. <i>Journal of Clinical Pharmacology</i> , 2018 , 58, 1550-1556	2.9	6
85	Correlation between entecavir penetration in peripheral blood mononuclear cells and HBV DNA decay during treatment of HBeAg-negative chronic hepatitis B. <i>Antiviral Therapy</i> , 2018 , 23, 373-377	1.6	2
84	Effect of pharmacogenetic markers of vitamin D pathway on deferasirox pharmacokinetics in children. <i>Pharmacogenetics and Genomics</i> , 2018 , 28, 17-22	1.9	4
83	Precision medicine for HIV: where are we?. <i>Pharmacogenomics</i> , 2018 , 19, 145-165	2.6	9
82	Clinical relevance of deferasirox trough levels in β -thalassemia patients. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2018 , 45, 213-216	3	3
81	Role of CYP24A1, VDR and GC gene polymorphisms on deferasirox pharmacokinetics and clinical outcomes. <i>Pharmacogenomics Journal</i> , 2018 , 18, 506-515	3.5	5
80	Therapeutic drug monitoring of voriconazole for treatment and prophylaxis of invasive fungal infection in children. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 197-203	3.8	23
79	Role of CYP1A1, ABCG2, CYP24A1 and VDR gene polymorphisms on the evaluation of cardiac iron overload in thalassaemia patients. <i>Pharmacogenetics and Genomics</i> , 2018 , 28, 199-206	1.9	1
78	A Common <i>mdr1</i> Gene Polymorphism is Associated With Changes in Linezolid Clearance. <i>Therapeutic Drug Monitoring</i> , 2018 , 40, 602-609	3.2	6
77	A simple UHPLC-PDA method with a fast dilute-and-shot sample preparation for the quantification of canrenone and its prodrug spironolactone in human urine samples. <i>Journal of Pharmacological and Toxicological Methods</i> , 2018 , 94, 29-35	1.7	3
76	Daclatasvir Plasma Levels in a Cohort of Patients with Hepatitis C Virus Infection Taking Methadone: A Prospective Analysis. <i>European Addiction Research</i> , 2018 , 24, 184-188	4.6	2

75	Pharmacokinetic Changes during Pregnancy According to Genetic Variants: a Prospective Study in HIV-Infected Patients Receiving Atazanavir-Ritonavir. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	2
74	Vitamin D pathway gene polymorphisms affecting daclatasvir plasma concentration at 2 weeks and 1 month of therapy. <i>Pharmacogenomics</i> , 2018 , 19, 701-707	2.6	0
73	Therapeutic drug monitoring-guided definition of adherence profiles in resistant hypertension and identification of predictors of poor adherence. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 2535-2543	3.8	19
72	Deferasirox pharmacokinetic evaluation in thalassaemia paediatric patients. <i>Journal of Pharmacy and Pharmacology</i> , 2017 , 69, 525-528	4.8	4
71	Role of simeprevir plasma concentrations in HCV treated patients with dermatological manifestations. <i>Digestive and Liver Disease</i> , 2017 , 49, 705-708	3.3	1
70	Association of vitamin D pathway SNPs and clinical response to interferon in a cohort of HBeAg-negative patients. <i>Pharmacogenomics</i> , 2017 , 18, 651-661	2.6	5
69	Pharmacogenetic analysis of hepatitis C virus related mixed cryoglobulinemia. <i>Pharmacogenomics</i> , 2017 , 18, 607-611	2.6	1
68	The role of ITPA and ribavirin transporter genes polymorphisms in prediction of ribavirin-induced anaemia in chronic hepatitis C Egyptian patients. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2017 , 44, 965-968	3	4
67	UHPLC-MS/MS method with sample dilution to test therapeutic adherence through quantification of ten antihypertensive drugs in urine samples. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017 , 142, 279-285	3.5	24
66	Role of vitamin D pathway gene polymorphisms on rifampicin plasma and intracellular pharmacokinetics. <i>Pharmacogenomics</i> , 2017 , 18, 865-880	2.6	5
65	Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: A prospective study. <i>Journal of Viral Hepatitis</i> , 2017 , 24, 850-857	3.4	25
64	Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients. <i>Pharmacogenomics</i> , 2017 , 18, 539-554	2.6	10
63	Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study. <i>Infection, Genetics and Evolution</i> , 2017 , 51, 167-172	4.5	3
62	Influence of ABCB11 and HNF4A genes on daclatasvir plasma concentration: preliminary pharmacogenetic data from the Kineti-C study. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 2846-2849	5.1	6
61	Pharmacokinetic evaluation of oral itraconazole for antifungal prophylaxis in children. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2017 , 44, 1083-1088	3	13
60	Circannual variation of mitotane and its metabolites plasma levels in patients with adrenocortical carcinoma. <i>Journal of Pharmacy and Pharmacology</i> , 2017 , 69, 1524-1530	4.8	6
59	A simple high performance liquid chromatography-mass spectrometry method for Therapeutic Drug Monitoring of isavuconazole and four other antifungal drugs in human plasma samples. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017 , 145, 718-724	3.5	14
58	Reasons to wait or to treat naive patients affected by chronic hepatitis C with low fibrosis stage and genotypes 2 or 3. <i>European Journal of Public Health</i> , 2017 , 27, 938-941	2.1	1

57	Treatment with daclatasvir and sofosbuvir for 24 weeks without ribavirin in cirrhotic patients who failed first-generation protease inhibitors. <i>Infection</i> , 2017 , 45, 103-106	5.8	9
56	Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs. <i>Clinical Pharmacokinetics</i> , 2017 , 56, 355-369	6.2	19
55	Evaluation of Posaconazole Pharmacokinetics in Adult Patients with Invasive Fungal Infection. <i>Biomedicines</i> , 2017 , 5,	4.8	12
54	Role of IL28B genotype in the liver stiffness increase in untreated patients with chronic hepatitis C. <i>Infection, Genetics and Evolution</i> , 2017 , 53, 195-198	4.5	6
53	Clinical pharmacology of tenofovir clearance: a pharmacokinetic/pharmacogenetic study on plasma and urines. <i>Pharmacogenomics Journal</i> , 2016 , 16, 514-518	3.5	18
52	UHPLC-MS/MS method with protein precipitation extraction for the simultaneous quantification of ten antihypertensive drugs in human plasma from resistant hypertensive patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016 , 129, 535-541	3.5	31
51	Role of pharmacogenetics on deferasirox AUC and efficacy. <i>Pharmacogenomics</i> , 2016 , 17, 561-72	2.6	13
50	UHPLC-MS/MS method with automated on-line solid phase extraction for the quantification of entecavir in peripheral blood mononuclear cells of HBV+ patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016 , 118, 64-69	3.5	16
49	Tenofovir clearance is reduced in HIV-positive patients with subclinical tubular impairment. <i>Aids</i> , 2016 , 30, 915-20	3.5	11
48	Ethambutol plasma and intracellular pharmacokinetics: A pharmacogenetic study. <i>International Journal of Pharmaceutics</i> , 2016 , 497, 287-92	6.5	9
47	The Role of IL28B Genotype in HCV-RNA Baseline Levels. <i>Intervirology</i> , 2016 , 59, 67-68	2.5	1
46	Vitamin D pathway gene polymorphisms as predictors of hepatitis C virus-related mixed cryoglobulinemia. <i>Pharmacogenetics and Genomics</i> , 2016 , 26, 307-10	1.9	8
45	Pharmacogenetics of ribavirin-induced anemia in HCV patients. <i>Pharmacogenomics</i> , 2016 , 17, 925-41	2.6	16
44	Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon. <i>Antiviral Research</i> , 2016 , 136, 32-36	10.8	8
43	Deferasirox pharmacokinetics evaluation in a woman with hereditary haemochromatosis and heterozygous β -thalassaemia. <i>Biomedicine and Pharmacotherapy</i> , 2016 , 84, 1510-1512	7.5	2
42	Efavirenz pharmacogenetics in a cohort of Italian patients. <i>International Journal of Antimicrobial Agents</i> , 2016 , 47, 117-23	14.3	21
41	Deferasirox AUC efficacy cutoff and role of pharmacogenetics. <i>European Journal of Clinical Pharmacology</i> , 2016 , 72, 1155-7	2.8	8
40	Entecavir plasma concentrations are inversely related to HBV-DNA decrease in a cohort of treatment-naïve patients with chronic hepatitis B. <i>International Journal of Antimicrobial Agents</i> , 2016 , 48, 324-7	14.3	6

39	Deferasirox pharmacokinetic and toxicity correlation in β -thalassaemia major treatment. <i>Journal of Pharmacy and Pharmacology</i> , 2016 , 68, 1417-1421	4.8	9
38	Intracellular accumulation of boceprevir according to plasma concentrations and pharmacogenetics. <i>International Journal of Antimicrobial Agents</i> , 2015 , 45, 657-61	14.3	8
37	Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment. <i>Archives of Virology</i> , 2015 , 160, 2009-17	2.6	7
36	VDR gene polymorphisms impact on anemia at 2 weeks of anti-HCV therapy: a possible mechanism for early RBV-induced anemia. <i>Pharmacogenetics and Genomics</i> , 2015 , 25, 164-72	1.9	10
35	Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study). <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 3096-9	5.1	14
34	Role of pharmacogenetic in ribavirin outcome prediction and pharmacokinetics in an Italian cohort of HCV-1 and 4 patients. <i>Biomedicine and Pharmacotherapy</i> , 2015 , 69, 47-55	7.5	12
33	Role of CYP27B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBeAg negative with PEG-interferon. <i>Journal of Viral Hepatitis</i> , 2015 , 22, 318-27	3.4	19
32	ABCB11 and ABCB1 gene polymorphisms impact on telaprevir pharmacokinetic at one month of therapy. <i>Biomedicine and Pharmacotherapy</i> , 2015 , 69, 63-9	7.5	12
31	Influence of single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness. <i>Pharmacogenomics Journal</i> , 2015 , 15, 263-71	3.5	16
30	Vitamin D pathway gene variants and HCV-2/3 therapy outcomes. <i>Antiviral Therapy</i> , 2015 , 20, 335-41	1.6	17
29	Intracellular and Plasma Trough Concentration and Pharmacogenetics of Telaprevir. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2015 , 18, 171-6	3.4	8
28	Effect of SNPs in human ABCB1 on daptomycin pharmacokinetics in Caucasian patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 307-8	5.1	8
27	Treatment optimization of naïve HCV-1 patients using IL28B, RVR and fibrosis stage. <i>Antiviral Research</i> , 2015 , 116, 45-7	10.8	5
26	Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevir. <i>Journal of Viral Hepatitis</i> , 2014 , 21, 260-3	3.4	23
25	Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner. <i>Antiviral Research</i> , 2014 , 109, 7-14	10.8	12
24	High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 241-5	5.1	24
23	Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 3061-6	5.1	34
22	The E genotype of hepatitis B: clinical and virological characteristics, and response to interferon. <i>Journal of Infection</i> , 2014 , 69, 81-7	18.9	20

21	Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon. <i>Antiviral Research</i> , 2014 , 102, 35-43	10.8	25
20	Identification of naïve HVC-4 patients who may be treated with pegylated-interferon and ribavirin according to IL28B polymorphisms. <i>Antiviral Research</i> , 2014 , 106, 105-10	10.8	9
19	Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients. <i>Antiviral Research</i> , 2013 , 100, 114-9	10.8	25
18	Estimating ribavirin plasma exposure: genetics or therapeutic drug monitoring?. <i>Journal of Hepatology</i> , 2013 , 59, 633-4	13.4	7
17	Development and validation of a new UPLC-PDA method to quantify linezolid in plasma and in dried plasma spots. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2013 , 936, 42-7	3.2	30
16	Ultra performance liquid chromatography PDA method for determination of tigecycline in human plasma. <i>Therapeutic Drug Monitoring</i> , 2013 , 35, 853-8	3.2	10
15	Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 907-10	5.1	18
14	Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D. <i>Liver International</i> , 2013 , 33, 580-5	7.9	31
13	Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane. <i>Pharmacogenetics and Genomics</i> , 2013 , 23, 293-300	1.9	29
12	HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC). <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2012 , 59, 109-16	3.5	53
11	Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2012 , 66, 376-80	3.5	24
10	Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices. <i>British Journal of Clinical Pharmacology</i> , 2012 , 74, 134-40	3.8	29
9	Development and validation of a new method to simultaneously quantify triazoles in plasma spotted on dry sample spot devices and analysed by HPLC-MS. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 2645-9	5.1	30
8	Prophylactic drug monitoring of itraconazole in an oncohematological pediatric patient population. <i>Therapeutic Drug Monitoring</i> , 2012 , 34, 604-6	3.2	5
7	Negative predictive value of IL28B, SLC28A2, and CYP27B1 SNPs and low RBV plasma exposure for therapeutic response to PEG/IFN-RBV treatment. <i>Therapeutic Drug Monitoring</i> , 2012 , 34, 722-8	3.2	30
6	Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment. <i>Therapeutic Drug Monitoring</i> , 2012 , 34, 165-70	3.2	37
5	Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics. <i>Aids</i> , 2012 , 26, 1529-33	3.5	33
4	Single-Nucleotide Polymorphisms of ABCB1 Gene Influence Intracellular Concentrations of Dasatinib. <i>Blood</i> , 2012 , 120, 4903-4903	2.2	1

3	Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4. <i>Hepatology</i> , 2011 , 54, 2278-9	11.2	25
2	A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2011 , 54, 779-88	3.5	55
1	Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 2976-8	5.9	53